PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25227893-10	2015	By contrast, LDN produced a caspase 3-independent, reactive oxygen species-dependent cell death.	LDN	13-16	caspase 3	Homo sapiens	28-37
21256121-5	2011	Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG+Vehicle cohorts.	LDN	53-56	myelin oligodendrocyte glycoprotein	Mus musculus	98-101
20636408-9	2011	Our modified HARP approach to left LDN is safe, effective and can be performed expeditiously.	LDN	35-38	ankyrin repeat and sterile alpha motif domain containing 4B	Homo sapiens	13-17
24569372-6	2014	Additionally, LDN/OSU-0212320 protected cultured neurons from glutamate-mediated excitotoxic injury and death via EAAT2 activation.	LDN	14-17	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	114-119
23546884-4	2013	LDN, which is known to antagonize the Toll-like Receptor 4 pathway and attenuate activated microglia, was utilized in these patients after conventional CRPS pharmacotherapy failed to suppress their recalcitrant CRPS symptoms.	LDN	0-3	toll like receptor 4	Homo sapiens	38-58
22249415-5	2012	Inhibition of endogenous BMP signalling using recombinant Noggin or small molecule inhibitor LDN-193189, on the other hand, opposed these phenotypic changes.	LDN	93-96	bone morphogenetic protein 1	Homo sapiens	25-28
22095982-6	2012	Long-term LDN administration to apolipoprotein E-/- mice increased ABCA1 immunoreactivity within intraplaque macrophages by 3.7-fold (n=8; P=0.03), reduced Oil Red O-positive lipid area by 50% (n=8; P=0.02), and decreased total plaque area by 43% (n=8; P=0.001).	LDN	10-13	apolipoprotein E	Mus musculus	32-48
22095982-6	2012	Long-term LDN administration to apolipoprotein E-/- mice increased ABCA1 immunoreactivity within intraplaque macrophages by 3.7-fold (n=8; P=0.03), reduced Oil Red O-positive lipid area by 50% (n=8; P=0.02), and decreased total plaque area by 43% (n=8; P=0.001).	LDN	10-13	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	67-72
22095982-8	2012	LDN treatment increased macrophage ABCA1 and ABCG1 expression, significantly raised cholesterol efflux to ApoA-1, and decreased foam cell formation.	LDN	0-3	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	35-40
22095982-8	2012	LDN treatment increased macrophage ABCA1 and ABCG1 expression, significantly raised cholesterol efflux to ApoA-1, and decreased foam cell formation.	LDN	0-3	ATP binding cassette subfamily G member 1	Mus musculus	45-50
22095982-8	2012	LDN treatment increased macrophage ABCA1 and ABCG1 expression, significantly raised cholesterol efflux to ApoA-1, and decreased foam cell formation.	LDN	0-3	apolipoprotein A-I	Mus musculus	106-112
22095982-9	2012	All preceding LDN-induced effects on cholesterol efflux were reversed by exogenous hepcidin administration, suggesting modulation of intracellular iron levels within macrophages as the mechanism by which LDN triggers these effects.	LDN	14-17	hepcidin antimicrobial peptide	Mus musculus	83-91
22095982-9	2012	All preceding LDN-induced effects on cholesterol efflux were reversed by exogenous hepcidin administration, suggesting modulation of intracellular iron levels within macrophages as the mechanism by which LDN triggers these effects.	LDN	204-207	hepcidin antimicrobial peptide	Mus musculus	83-91
20975079-9	2010	Imiquimod in combination with OGF or a low dose of naltrexone (LDN; known to upregulate the OGF-OGFr axis) had no greater inhibitory response on DNA synthesis than either OGF or LDN alone.	LDN	63-66	opioid growth factor receptor	Mus musculus	96-100
11982475-9	2002	RESULTS: In the LDN group, mean ADH levels during pneumoperitoneum and 30 minutes postinsufflation were significantly higher compared with preinsufflation values (P<.001).	LDN	16-19	arginine vasopressin	Homo sapiens	32-35
19855075-5	2009	Over 33% of the MOG-treated animals receiving LDN did not exhibit behavioral signs of disease, and the severity and disease index of the LDN-treated mice were markedly reduced from cohorts injected with vehicle.	LDN	46-49	myelin oligodendrocyte glycoprotein	Mus musculus	16-19
19855075-5	2009	Over 33% of the MOG-treated animals receiving LDN did not exhibit behavioral signs of disease, and the severity and disease index of the LDN-treated mice were markedly reduced from cohorts injected with vehicle.	LDN	137-140	myelin oligodendrocyte glycoprotein	Mus musculus	16-19
17241397-3	2007	Galectin-3 recognizes the GalNAcbeta1-4GlcNAc (LDN) epitope present on many helminth antigens, including those of the schistosome eggs.	LDN	47-50	lectin, galactose binding, soluble 3	Mus musculus	0-10
16728562-1	2006	beta1,4-N-acetylgalactosaminyltransferase III (beta4GalNAc-T3), which was recently cloned and identified, exhibits GalNAc transferase activity toward a GlcNAcbeta residue with beta1,4-linkage, forming the N,N"-diacetyllactosediamine, GalNAcbeta1,4GlcNAc (LacdiNAc or LDN).	LDN	267-270	beta-1,4-N-acetyl-galactosaminyltransferase 3	Homo sapiens	0-45
16728562-1	2006	beta1,4-N-acetylgalactosaminyltransferase III (beta4GalNAc-T3), which was recently cloned and identified, exhibits GalNAc transferase activity toward a GlcNAcbeta residue with beta1,4-linkage, forming the N,N"-diacetyllactosediamine, GalNAcbeta1,4GlcNAc (LacdiNAc or LDN).	LDN	267-270	beta-1,4-N-acetyl-galactosaminyltransferase 3	Homo sapiens	47-61
15653684-3	2005	To better understand LDN biosynthesis and regulation, we stably expressed the cDNA encoding the Caenorhabditis elegans beta1,4-N-acetylgalactosaminyltransferase (GalNAcT), which generates LDN in vitro, in Chinese hamster ovary (CHO) Lec8 cells, to establish L8-GalNAcT CHO cells.	LDN	21-24	beta-1,4-N-acetyl-galactosaminyltransferase 1	Homo sapiens	162-169
34326841-7	2021	We report that ME/CFS patients taking LDN have restored TRPM3-like ionic currents in NK cells.	LDN	38-41	transient receptor potential cation channel subfamily M member 3	Homo sapiens	56-61
34608584-4	2022	The BMP pathway was inhibited with the small molecule inhibitor LDN193189 hydrochloride (LDN).	LDN	89-92	bone morphogenetic protein 1	Homo sapiens	4-7
33841104-5	2021	Here, we used two different compounds, ceftriaxone and LDN/OSU-0212320 (LDN), to upregulate GLT-1 in healthy wild-type mice.	LDN	55-58	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	92-97
32765993-10	2020	The second case is a 66-year-old female with documented SS based on a history of dry eyes and dry mouth, joint pain, and elevated anti-SSA and anti-SSB antibodies whose joint symptoms responded to treatment with LDN.	LDN	212-215	small RNA binding exonuclease protection factor La	Homo sapiens	148-151
33664680-7	2021	In this open-label case series, patients were treated with low dose naltrexone (LDN), a pure opioid receptor antagonist that, we hypothesize, treats OIH and FM by restoring endogenous opioid tone.	LDN	80-83	fibromodulin	Homo sapiens	157-159
33141073-11	2020	Immunohistochemistry with Olig2 (pan-oligodendrocyte marker) and myelin basic protein (MBP) revealed that OGF and LDN treatment restored the area (%) of MBP and number of oligodendrocytes to that of normal spinal cord (~75 %).	LDN	114-117	oligodendrocyte transcription factor 2	Mus musculus	26-31
33141073-11	2020	Immunohistochemistry with Olig2 (pan-oligodendrocyte marker) and myelin basic protein (MBP) revealed that OGF and LDN treatment restored the area (%) of MBP and number of oligodendrocytes to that of normal spinal cord (~75 %).	LDN	114-117	myelin basic protein	Mus musculus	65-85
30958613-10	2019	Low-dose naltrexone (LDN) may also exert an anti-inflammatory action through its antagonist effect on toll-like receptor 4 found on macrophages.	LDN	21-24	toll like receptor 4	Homo sapiens	102-122
31370144-5	2019	LDN-POx nanoparticles were equal in effects as the native compound in vitro.	LDN	0-3	proline dehydrogenase 1	Homo sapiens	4-7
31370144-8	2019	Moreover, treatment with LDN and LDN-POx resulted in reduced levels of pro-metastatic markers, a decrease of carcinoma cell adhesion, as well as inhibition of extra-cellular vesicle (ECV)-mediated transfer of viral invasive factor LMP1.	LDN	25-28	PDZ and LIM domain 7	Homo sapiens	231-235
31835085-15	2020	In animals treated with a combination of LDN and 5FU a maximal downregulation of the antiapoptotic mediator BCL2 was observed.	LDN	41-44	B cell leukemia/lymphoma 2	Mus musculus	108-112
30248938-3	2018	Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opioid-receptor blockade.	LDN	21-24	toll like receptor 4	Homo sapiens	135-155
26202376-9	2016	We have previously demonstrated that modulation of the OGF-OGFr axis results in alleviation from relapse-remitting EAE, and that CNS-infiltrating CD3(+) T cells are diminished with exogenous OGF or intermittent blockade with LDN administration.	LDN	225-228	CD3 antigen, epsilon polypeptide	Mus musculus	146-149
26096891-6	2015	Translational activators of EAAT2/GLT-1, such as ceftriaxone and LDN/OSU-0212320, have been described to have significant protective effects in animal models of amyotrophic lateral sclerosis and epilepsy.	LDN	65-68	solute carrier family 1 member 2	Homo sapiens	28-33
26096891-6	2015	Translational activators of EAAT2/GLT-1, such as ceftriaxone and LDN/OSU-0212320, have been described to have significant protective effects in animal models of amyotrophic lateral sclerosis and epilepsy.	LDN	65-68	solute carrier family 1 member 2	Homo sapiens	34-39